Sol-Gel Technologies Ltd SLGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $76.36
- Day Range
- $73.53–78.28
- 52-Week Range
- $7.62–97.97
- Bid/Ask
- $29.58 / $117.58
- Shares Outstanding
- 3.27M
- Market Cap
- $241.74M
- Volume/Avg
- 756 / 34,611
Key Statistics
- Price/Earnings (Normalized)
- 32.22
- Price/Sales
- 11.33
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 28
- Website
- https://www.sol-gel.com
Valuation
|
Metric
|
SLGL
|
|---|---|
Price/Earnings (Normalized) | 32.22 |
Price/Book Value | 4.75 |
Price/Sales | 11.33 |
Price/Cash Flow | — |
Price/Earnings
SLGL
Financial Strength
|
Metric
|
SLGL
|
|---|---|
Quick Ratio | 8.54 |
Current Ratio | 8.84 |
Interest Coverage | — |
Quick Ratio
SLGL
Profitability
|
Metric
|
SLGL
|
|---|---|
Return on Assets (Normalized) | −2.76% |
Return on Equity (Normalized) | −3.43% |
Return on Invested Capital (Normalized) | −7.37% |
Return on Assets
SLGL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yg#z&&@ | LOCK|w@ycd | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|XlK#!&# | LOCK|HK^R@ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<^B<G$ | LOCK|vR | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|sWF@!@P | LOCK|d&lC | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%fSy&? | LOCK|lD | $36B | |||
| Moderna Inc
MRNA
| LOCK|%$>z>NW | LOCK|<& | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Lk@%h$&> | LOCK|R#@L | $25B | |||
| Incyte Corp
INCY
| LOCK|f#&Kzk& | LOCK|@# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|J<T#fc | LOCK|%$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%t<#%$n | LOCK|p< | $17B |
United States